Drug Trial Radar · NCT01074697
Efficacy of Two Antiemetic Regimens in Patients Receiving Radiotherapy and Concomitant Weekly Cisplatin
Last checked: Nov 19, 2026Latest source record: Apr 24, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
246
Actual
Start
Apr 2010
Primary completion
Apr 2015
Study completion Apr 2015
Sponsor
- Lead sponsor
- Odense University HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Helsinn Healthcare SA
- First posted
- Feb 24, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Supportive care
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
GAND-emesis is a multinational, randomized, double-blind, placebo-controlled, parallel-group study to investigate the efficacy and tolerability of a neurokinin1 receptor antagonist (fosaprepitant dimeglumine) in combination with an antiemetic (anti-nausea-and-vomiting) control regimen (palonosetron and dexamethasone) in patients with a gynaecological cancer diagnosis, who are scheduled to receive radiotherapy and weekly chemotherapy. The study aims at investigating if a three-drug antiemetic regimen is superior to a two-drug regimen (standard treatment) in preventing nausea and vomiting in patients receiving radiotherapy and weekly chemotherapy. A pilot study demonstrated that approximately 50% of patients will experience nausea and vomiting when offered a two-drug antiemetic regimen, and it is expected that addition of a third drug (a neurokinin1 receptor antagonist) can increase the proportion of patients with no vomiting in the course of combined chemo-radiotherapy.
Conditions
- Nausea
- Vomiting
- Genital Neoplasms, Female
Interventions
Fosaprepitant dimeglumineDrug
Addition of fosaprepitant dimeglumine 150 mg IV single dose weekly (before chemotherapy) to dexamethasone and palonosetron.
PlaceboDrug
Saline water
Primary outcomes
What the sponsor says the trial is designed to measure.
- To compare fosaprepitant dimeglumine, palonosetron, and dexamethasone with palonosetron, dexamethasone, and placebo with respect to efficacy; the proportion of subjects with no vomiting during five weeks of radiotherapy and concomitant weekly cisplatin.Time frame: 35 days
Locations
8 sites in 4 countries. Site status is shown where the registry gives one.
RAH Cancer Centre, Royal Adelaide Hospital
Adelaide SA, Australia
Department of Oncology
Aarhus, Denmark
Rigshospitalet, Finsen Centret
Copenhagen, Denmark
Herlev Hospital
Herlev, Denmark
Department of Oncology, Odense University Hospital
Odense, Denmark
Vivantes Klinikum Neukolln
Berlin, Germany
Universitatsklinikum Schleswig Holstein
Kiel, Germany
The Norwegian Radium Hospital
Oslo, Norway
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.